Skip to content

BioArctic is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs.

Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential.

February 3, 2023

Full Year Report 2022

BioArctic published the company’s Full Year Report for the period January –December 2022 on Friday, February 3, 2023, at 08:00 a.m. CET.

For more information, please contact:


Oskar Bosson

Vice President Investor Relations & Communications